Sedat Jacques, Chau Yves, Mondot Lydiane, Chemla Richard, Lonjon Michel, Padovani Bernard
Unité de Neurointerventionnelle, Hôpital Saint-Roch, 5 rue Pierre Devoluy, Nice, 06000, France,
Neuroradiology. 2014 Feb;56(2):145-53. doi: 10.1007/s00234-013-1301-3. Epub 2013 Nov 27.
Thromboembolic complications are the most frequent perioperative complications of endovascular treatment of intracranial aneurysms. Even if the effectiveness of glycoprotein IIb/IIIa inhibitors has been reported, the outcomes in published clinic data are contradictory. This study aims to assess the effectiveness and the safety of eptifibatide in thromboembolic complications during intracranial aneurysm embolization procedure.
Between 2006 and 2012, 650 patients with intracranial aneurysm were treated using endovascular coil embolization, and in 62 cases (9.5 %), an intra-arterial thrombus developed. Glycoprotein IIb/IIIa inhibitor was administrated in 45 of them who required a rescue treatment. These 45 patients were treated with an intra-arterial bolus (0.2 mg/kg) of eptifibatide. We respectively reviewed the angiographic and clinical outcomes, and the periprocedural complications of the rescue treatment.
No intra- or early postoperative (48 h) bleeding was observed after treatment. A total recovery of the entire arterial tree (TICI 3) was established in 28 cases (62.2 %), a partial revascularization in 13 cases (28.8 %) (5 TICI 2A and 8 TICI 2B), and no revascularization or reperfusion (TICI 0 or TICI 1) in 4 cases (9 %). Eptifibatide was more effective on proximal obstructions and in-stent occlusions than on peripheral distal thrombus, which were completely disintegrated one time out of three.
Intra-operative intra-arterial use of eptifibatide does not imply an increase of hemorrhagic events. Even if eptifibatide allows for a high rate of arterial recanalization, its effectiveness seems to be less important in cases of distal occlusions.
血栓栓塞并发症是颅内动脉瘤血管内治疗最常见的围手术期并发症。尽管已有报道称糖蛋白IIb/IIIa抑制剂有效,但已发表的临床数据结果相互矛盾。本研究旨在评估依替巴肽在颅内动脉瘤栓塞术期间血栓栓塞并发症中的有效性和安全性。
2006年至2012年期间,650例颅内动脉瘤患者接受了血管内弹簧圈栓塞治疗,其中62例(9.5%)发生了动脉内血栓形成。其中45例需要抢救治疗的患者接受了糖蛋白IIb/IIIa抑制剂治疗。这45例患者接受了动脉内推注(0.2mg/kg)依替巴肽治疗。我们分别回顾了血管造影和临床结果以及抢救治疗的围手术期并发症。
治疗后未观察到术中或术后早期(48小时)出血。28例(62.2%)实现了整个动脉树的完全再通(TICI 3级),13例(28.8%)实现了部分血管再通(5例TICI 2A级和8例TICI 2B级),4例(9%)未实现血管再通或再灌注(TICI 0级或TICI 1级)。依替巴肽对近端阻塞和支架内闭塞的效果比对周围远端血栓更有效,后者在三分之一的情况下完全溶解。
术中动脉内使用依替巴肽并不意味着出血事件增加。尽管依替巴肽可实现较高的动脉再通率,但其在远端闭塞病例中的有效性似乎不太重要。